


REMARKS

Applicants have attached an abstract on a separate sheet of paper as required by U.S. practice. Applicants have amended the specification for purposes of adding the priority information. Claims 1, 2, 3, 4, 5, and 9 have been amended for purposes of placing the claims in U.S. format. Claims 6, 7, 8, 12, and 13 have been cancelled. Claims 14 and 15 have been added. Support for claim 14 is provided in the specification at pages 120 – 121. Support for claim 15 is provided in the specification at page 121. Claims 1 – 5, and 9 – 11, 14 and 15 are pending in the application. No new matter has been added. It is respectfully submitted that the present application is in condition for consideration. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Date:

September 26, 2006


Karen L. Prus
Attorney of Record, Reg. No 39,337

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-2192
Fax: 919-483-7988